1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ESMO: Padcev/Keytruda Combo Edges Closer To First-Line Bladder Cancer Filing

Big Boost For Seagen

 
• By Kevin Grogan

Full data presented at ESMO from a closely watched trial of Seagen/Astellas’s Padcev and Merck & Co’s Keytruda should support regulatory approval of the combination in cisplatin-ineligible first-line metastatic urothelial cancer patients but concerns over duration of treatment remain.

First-line approval is the target for Padcev/Keytruda combo • Source: Shutterstock

The chances of the much-touted combination of Seagen Inc./Astellas Pharma, Inc.'s Padcev and Merck & Co., Inc.'s Keytruda getting approval in first-line urothelial cancer would appear to have improved on the back of more positive data presented at the European Society for Medical Oncology conference in Paris.

Cohort K of the Phase Ib/II EV-103/KEYNOTE-869 trial compared a combination of the antibody-drug conjugate Padcev (enfortumab vedotin) and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

More from R&D

Amycretin Heads For Phase III In Type 2 Diabetes

 
• By Joseph Haas

New Phase II data in type 2 diabetes for Novo Nordisk’s GLP-1/amylin agonist amycretin shows significant weight loss and HbA1c-lowering potential. A Phase III trial is planned.

Kelonia Draws Attention With In Vivo CAR-T Myeloma Data

 
• By Alaric DeArment

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

Zai Lab Takes Lead In DLL3 Lung Cancer ADC Race

 
• By Andrew McConaghie

Having built its reputation as the ‘Gateway to China’ for global firms, Zai is going global itself, moving its potential first-in-class ADC into Phase III development.